EY’s “The new revenue recognition standard — life sciences” report. The new revenue standard could result in significant changes in practice for life sciences entities.Continue reading
Category Archives: AZBio News
HTG Molecular Diagnostics Announces $16 Million Term Loan Agreement With Silicon Valley Bank and Oxford Finance
HTG Molecular Diagnostics (“HTG”) today announced that it has closed a growth capital term loan facility with Silicon Valley Bank and Oxford Finance (SVB/Oxford). The loan facility provides HTG with up to $16 million of available proceeds, with $11 million funded at the initial closing this month.Continue reading
TGen receives approval for patient enrollment in brain cancer clinical trial
Glioblastoma (GBM) pilot trial funded by Ivy FoundationContinue reading
ASU Biodesign Institute has $1.5 billion impact on Arizona economy
Arizona State University’s Biodesign Institute has made an economic impact of $1.5 billion in its first decade of operation, according to a study by the Seidman Research Institute at ASU’s W. P. Carey School of Business.
Jack Jewett Named Arizona Bioscience Leader of the Year
Jack B. Jewett, President & CEO of the Flinn Foundation, to be honored with the Jon W. McGarity Arizona Bioscience Leader of the Year Award by the Arizona BioIndustry Association.
Riddell and TGen Team Up with Arizona State University’s Football Program to Further Genetic Research into Athlete Concussion Detection and Treatment
2014 Football Season Marks the Second Year of the Research Partnership; Study Using Sun Devils’ Head Impact Data and Genetic Information Could Help Improve Player Protection, Inform New Helmet Designs and Refine Smart Helmet TechnologyContinue reading
Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Glioblastoma Multiforme
PHOENIX, AZ–(Aug 25, 2014) – Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its pharmaceutical cannabidiol (CBD) for the treatment of glioblastoma multiforme (GBM), the most common and most aggressive malignant primary brain tumor in humans.Continue reading
Share Your Talents and Help Launch AZ Biotech Companies
Looking for an Opportunity to Create IMPACT? Explore Serving as a TLA Partner with a Purpose.
Ventana Planning New Distribution Center in Marana Arizona
Construction of a 60,000-square-foot logistics and distribution center for Ventana Medical Systems is scheduled to begin by year’s end in Marana.Continue reading